scholarly journals The impact of cancer treatment on quality of life in patients with pancreatic and periampullary cancer: a propensity score matched analysis

HPB ◽  
2021 ◽  
Author(s):  
Tara M. Mackay ◽  
Willemieke P.M. Dijksterhuis ◽  
Anouk E.J. Latenstein ◽  
Lydia G. van der Geest ◽  
Mirjam A.G. Sprangers ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Propensity Score ◽  
Cancer Treatment ◽  
Periampullary Cancer ◽  
The Impact

scholarly journals The impact of lymphedema on health-related quality of life up to 10 years after breast cancer treatment

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Mads G. Jørgensen ◽  
Navid M. Toyserkani ◽  
Frederik G. Hansen ◽  
Anette Bygum ◽  
Jens A. Sørensen
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Cancer Treatment ◽  
Breast Cancer Treatment ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
The Impact

AbstractThe impact of breast cancer-related lymphedema (BCRL) on long-term quality of life is unknown. The aim of this study was to investigate the impact of BCRL on health-related quality of life (HRQoL) up to 10 years after breast cancer treatment. This regional population-based study enrolled patients treated for breast cancer with axillary lymph node dissection between January 1st 2007 and December 31th 2017. Follow up and assessments of the included patients were conducted between January 2019 and May 2020. The study outcome was HRQoL, evaluated with the Lymphedema Functioning, Disability and Health Questionnaire, the Disabilities of the Arm, Shoulder and Hand Questionnaire and the Short Form (36) Health Survey Questionnaire. Multivariate linear logistic regression models adjusted for confounders provided mean score differences (MDs) with 95% confidence intervals in each HRQoL scale and item. This study enrolled 244 patients with BCRL and 823 patients without BCRL. Patients with BCRL had significantly poorer HRQoL than patients without BCRL in 16 out of 18 HRQoL subscales, for example, in physical function (MDs 27, 95%CI: 24; 30), mental health (MDs 24, 95%CI: 21; 27) and social role functioning (MDs 20, 95%CI: 17; 23). Age, BMI, BCRL severity, hand and dominant arm affection had only minor impact on HRQoL (MDs < 5), suggesting a high degree of inter-individual variation in coping with lymphedema. This study showed that BCRL is associated with long-term impairments in HRQoL, especially affecting the physical and psychosocial domains. Surprisingly, BCRL diagnosis rather than clinical severity drove the largest impairments in HRQoL.

THE IMPACT OF CANCER TREATMENT ON QUALITY OF LIFE OUTCOMES FOR PATIENTS WITH LOCALIZED PROSTATE CANCER

2001 ◽  
Vol 166 (5) ◽  
pp. 1804-1810 ◽  
Author(s):  
CONSTANCE G. BACON ◽  
EDWARD GIOVANNUCCI ◽  
MARCIA TESTA ◽  
ICHIRO KAWACHI
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Cancer Treatment ◽  
Localized Prostate Cancer ◽  
Life Outcomes ◽  
Quality Of Life Outcomes ◽  
The Impact

scholarly journals The Impact of New Technologies on Wages in Colombia: An Analysis With the 2018 Quality-of-Life Survey

2021 ◽  
Author(s):  
Fernando Barrios Aguirre ◽  
Martha Patricia Castellanos Saavedra ◽  
Diana Maritza Álvarez Ovalle ◽  
Nancy Milena Riveros Chávez
Keyword(s):  
Quality Of Life ◽  
Propensity Score ◽  
Propensity Score Matching ◽  
Computer Use ◽  
New Technologies ◽  
Positive Impact ◽  
Public Policies ◽  
Learning Technologies ◽  
The Impact

This document evaluates the impact of computer use on wages in Colombia in 2018. For this analysis, a Propensity Score Matching model is used to evaluate the impact of the use of learning technologies on the wages and years of education of Colombians, based on the 2018 quality of life survey. The results show that the use of the computer, laptop, tablet, internet, transferred files, Excel and radio for learning have a positive impact on the wages of Colombians. This research allows a better understanding of the technological effects on wages and provides information for the design of public policies in the development of technological skills.

scholarly journals The positive impact of dental care on the patient's quality of life after cancer treatment: a case report

2020 ◽  
Vol 9 (9) ◽  
pp. e650997639
Author(s):  
Caroline Gomes Carvalho ◽  
João Victor Frazão Câmara ◽  
Paulo Sérgio da Silva Santos
Keyword(s):  
Quality Of Life ◽  
Case Report ◽  
Oral Health ◽  
Cancer Treatment ◽  
Dental Treatment ◽  
Positive Impact ◽  
Antineoplastic Treatment ◽  
After Cancer ◽  
The Impact

Objective: To report the case of a patient after cancer treatment and evaluate the impact of oral health on quality of life, through the Oral Health Impact Profile (OHIP-14) before, during, and after dental treatment. Methodology: A patient after antineoplastic treatment attended the clinic specialized. In all consultations, OHIP-14 was applied. Case report: A 68-year-old man diagnosed with keratinizing squamous cell carcinoma of the larynx (T3N0MX), undergoing chemotherapy and adjuvant radiotherapy (2878.2 Grays) and vertical partial laryngectomy surgery without ganglionic emptying. After CT, he complained of tooth loss and discomfort in the tongue after radiotherapy. Ex-drinker for 5 years, ex-smoker for 6 months, but alcoholic for> 10 years and smoker <50 years. Side effects of antineoplastic treatment included labial dryness, hyposalivation, dental fractures, residual roots, changes in swallowing, pain during mouth opening, and cervical movement. The results OHIP-14 was medium (17.85), weak (3.52), weak (2.84) and null impact of oral health on quality of life in the initial consultation, throughout the dental treatment, at the end of dental treatment and 1 year and 2 months after dental treatment, respectively. There was a high impact on psychological discomfort (3.55), medium on psychological disability (1.6), and functional limitation (2.04), in 2015, 2017, and 2018, respectively. Conclusion: The performance of the dentist on the late oral effects of chemotherapy and radiotherapy had a positive impact on improving the quality of life after cancer treatment, with the help of the multidisciplinary team. 

Optimizing the assessment of quality of life after laryngeal cancer treatment

2004 ◽  
Vol 118 (6) ◽  
pp. 432-438 ◽  
Author(s):  
V. Lee-Preston ◽  
I. N. Steen ◽  
A. Dear ◽  
C. G. Kelly ◽  
A. R. Welch ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cancer Treatment ◽  
Head And Neck ◽  
Laryngeal Cancer ◽  
Nottingham Health Profile ◽  
Life Assessment ◽  
High Morbidity ◽  
Wide Range ◽  
The Impact

Reports of the impact of larynx cancer treatment modality on quality of life are conflicting, in part due to varying study methodology. The aims of this study were to (1) provide preliminary comparisons of quality of life following radiotherapy or combination therapy; (2) evaluate a number of measures of quality of life and thereby (3) inform future prospective studies. Thirty-six laryngeal cancer patients, 24 following radiotherapy, 12 following radiotherapy and laryngectomy completed the Functional Assessment of Cancer Therapy (FACT) - General/Head and Neck subscale; Nottingham Health Profile (NHP); and the Hospital Anxiety and Depression scale (HAD), three to 12 months post-treatment. Results showed trends towards a less good quality of life in the combined therapy group over a wide range of outcomes, significant for the disease specific FACT head and neck subscale, NHP emotion (p = 0.04) and isolation (p = 0.027). To the authors' knowledge, however, this is the first demonstration of greater impact of laryngeal cancer on quality of life in younger subjects, who had lower scores among others on emotional wellbeing (p = 0.015) and anxiety (p = 0.035). Younger patients thus appear more likely to need more intensive support through treatment. Many of the physical and psychosocial domains derived from the three tools used were highly correlated. In other words, given the known high morbidity of the disease and its treatment, the selection of tools for head and neck quality of life assessment may be much less important than their universal application.

scholarly journals The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model

2016 ◽  
Vol 20 (13) ◽  
pp. 1-588 ◽  
Author(s):  
Louise Crathorne ◽  
Nicola Huxley ◽  
Marcela Haasova ◽  
Tristan Snowsill ◽  
Tracey Jones-Hughes ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cost Effectiveness ◽  
Cancer Treatment ◽  
Economic Model ◽  
Cochrane Library ◽  
Controlled Trials ◽  
Erythropoiesis Stimulating Agents ◽  
Considerable Uncertainty ◽  
The Impact

BackgroundAnaemia is a common side effect of cancer treatments and can lead to a reduction in quality of life. Erythropoiesis-stimulating agents (ESAs) are licensed for use in conjunction with red blood cell transfusions to improve cancer treatment-induced anaemia (CIA).ObjectiveTo investigate the effectiveness and cost-effectiveness of ESAs in anaemia associated with cancer treatment (specifically chemotherapy).Data sourcesThe following databases were searched from 2004 to 2013: The Cochrane Library, MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE, Web of Science, Cumulative Index to Nursing and Allied Health Literature, British Nursing Index, Health Management Information Consortium, Current Controlled Trials and ClinicalTrials.gov. The US Food and Drug Administration and European Medicines Agency websites were also searched. Bibliographies of included papers were scrutinised for further potentially includable studies.Review methodsThe clinical effectiveness review followed principles published by the NHS Centre for Reviews and Dissemination. Randomised controlled trials (RCTs), or systematic reviews of RCTs, of ESAs (epoetin or darbepoetin) for treating people with CIA were eligible for inclusion in the review. Comparators were best supportive care, placebo or other ESAs. Anaemia- and malignancy-related outcomes, health-related quality of life (HRQoL) and adverse events (AEs) were evaluated. When appropriate, data were pooled using meta-analysis. An empirical health economic model was developed comparing ESA treatment with no ESA treatment. The model comprised two components: one evaluating short-term costs and quality-adjusted life-years (QALYs) (while patients are anaemic) and one evaluating long-term QALYs. Costs and benefits were discounted at 3.5% per annum. Probabilistic and univariate deterministic sensitivity analyses were performed.ResultsOf 1457 titles and abstracts screened, 23 studies assessing ESAs within their licensed indication (based on start dose administered) were included in the review. None of the RCTs were completely aligned with current European Union licenses. The results suggest a clinical benefit from ESAs for anaemia-related outcomes and an improvement in HRQoL scores. The impact of ESAs on AEs and survival remains highly uncertain, although point estimates are lower, confidence intervals are wide and not statistically significant. Base-case incremental cost-effectiveness ratios (ICERs) for ESA treatment compared with no ESA treatment ranged from £19,429 to £35,018 per QALY gained, but sensitivity and scenario analyses demonstrate considerable uncertainty in these ICERs, including the possibility of overall health disbenefit. All ICERs were sensitive to survival and cost.LimitationsThe relative effectiveness of ESAs was not addressed; all ESAs were assumed to have equivalent efficacy. No studies were completely aligned with their European labelling beyond the starting dose evaluated. There is questionable generalisability given that the included trials were published > 20 years ago and there have been many changes to chemotherapy as well as to the quality of supportive treatment. Trial quality was moderate or poor and there was considerable unexplained heterogeneity for a number of outcomes, particularly survival, and evidence of publication bias. Adjustments were not made to account for multiple testing.ConclusionsESAs could be cost-effective when used closer to licence, but there is considerable uncertainty, mainly because of unknown impacts on overall survival.Study registrationThis study is registered as PROSPERO CRD42013005812.FundingThe National Institute for Health Research Health Technology Assessment programme.

scholarly journals Effect of capecitabine combined with irinotecan on the safety of colon cancer treatment, patients’ adverse reactions and quality of life

2021 ◽  
Vol 20 (11) ◽  
pp. 2413-2418
Author(s):  
Ingjuan Fan ◽  
Qing Li ◽  
Weijie Zhong ◽  
Shuang He ◽  
Kangbao Li
Keyword(s):  
Quality Of Life ◽  
Colon Cancer ◽  
Cancer Treatment ◽  
Cancer Patients ◽  
Adverse Reactions ◽  
Clinical Prognosis ◽  
Group A ◽  
Group B ◽  
The Impact

Purpose: To study the impact of the combination of capecitabine and irinotecan on the safety of colon cancer treatment, adverse reactions and wellbeing of patients.Methods: Colon cancer subjects (n =120) admitted to Guangzhou First People’s Hospital, Guangzhou, China were assigned equally to two groups (A and B) according to their order of admission, and they received intravenous infusion of irinotecan. In addition, group A patients were administered capecitabine, but those in B group were given tegafur, gimeracil and oteracil porassium. The patients in groups A and B were compared with respect to the incidence of unwanted effects, quality of life (QoL), and overall clinical efficacy of the treatments.Results: Cases of nausea and vomiting, delayed diarrhea and sensory neuropathy of the patients were significantly reduced in group A, relative to group B. Moreover, QoL score after treatment was markedly higher in group A than in group B, while the objective response rate (ORR) of colon cancer patients in group A was also significantly higher than that in group B (p < 0.05). However, no obvious difference in disease control rate (DCR) was observed between groups A and B (p > 0.05).Conclusion: Combined capecitabine and irinotecan therapy effectively improves clinical prognosis, reduces the incidence of adverse reactions, and is safe in colon cancer patients. Therefore, the combined treatment may be beneficial in the management of colon cancer.

Sign in / Sign up

Export Citation Format

Share Document